+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
ID06455449

Evaluating Weekly Subcutaneous Anifrolumab Added to Standard Treatment Versus Placebo in Adults With Polymyositis and Dermatomyositis

Led by AstraZeneca · Updated on 2026-09-24

240

Participants Needed

237

Research Sites

65 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of subcutaneous anifrolumab injections compared to placebo in adults with moderate to severe Idiopathic Inflammatory Myopathies IIM, including polymyositis PM and dermatomyositis DM. This Phase III, multicenter, randomized, placebo-controlled, and double-blind study adds anifrolumab or placebo to participants standard of care treatment to assess overall disease activity. Participants receive either anifrolumab or a matched placebo by subcutaneous injection once weekly for 52 weeks while continuing their standard treatments. After this period, all participants have the option to receive open-label anifrolumab weekly for an additional 52 weeks. This design allows researchers to compare the effects of anifrolumab against placebo and then observe longer-term effects when all receive anifrolumab. Throughout the study, participants undergo regular assessments including the Total Improvement Score TIS at 52 weeks as the main outcome. Additional evaluations include muscle strength testing, corticosteroid dosage monitoring, skin disease activity, and itch severity up to 52 weeks. Safety and disease activity improvements for both PM and DM participants are closely monitored. The study lasts up to approximately two years, including both blinded and open-label treatment phases.

CONDITIONS

Brief Title

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

Research Team

A

AstraZeneca Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here